ACOTEC-B (06669) surged over 12% in afternoon trading. As of press time, the stock was up 7.84% to HK$12.11 with a turnover of HK$18.90 million.
On the news front, ACOTEC-B recently announced that the group received registration approval for its micro guidewire from the Beijing Municipal Drug Administration. The micro guidewire is suitable for routine peripheral vascular use, designed to guide and position diagnostic or therapeutic devices. The company will launch marketing activities in China at an appropriate time.
Additionally, ACOTEC-B plans to hold a board meeting on August 26 to approve its interim results.
Notably, in December 2022, ACOTEC-B announced that Boston Scientific launched a takeover offer for the company at HK$20 per share for no more than 65% of ACOTEC-B's shares, representing a controlling stake. The estimated transaction value was approximately US$523 million. Upon completion of the transaction, Boston Scientific would become ACOTEC-B's controlling company.
In July 2023, both parties signed a cooperation framework agreement and service framework agreement, under which they will collaborate in areas including global product commercialization, product manufacturing services, and product research and development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.